Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
October 19, 2024 08:00 ET
|
Nurix Therapeutics, Inc.
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and...
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
October 18, 2024 17:05 ET
|
Regeneron Pharmaceuticals, Inc.
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the...
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
October 18, 2024 17:00 ET
|
F. Hoffmann-La Roche Ltd
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American,...
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
October 18, 2024 12:39 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the American...
Following the Success Sequence has a BIG impact on young adult mental health
October 18, 2024 11:30 ET
|
The Institute for Family Studies
Charlottesville, VA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- New research from the Institute for Family Studies shows the remarkably positive mental health impact of following the Success Sequence. The...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
October 18, 2024 06:47 ET
|
Novartis Pharma AG
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
October 17, 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024...
SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
October 17, 2024 14:35 ET
|
SpyGlass Pharma, Inc.
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
Les présentations de Theratechnologies lors de l’IDWeek mettent en évidence l’incidence de l’excès de graisse viscérale abdominale sur le risque de maladie cardiovasculaire chez les personnes vivant avec le VIH
October 17, 2024 14:00 ET
|
Theratechnologies
MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
October 17, 2024 14:00 ET
|
Theratechnologies
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...